Sight, switched back on: blind patients found doorways again after gene therapy built on Nobel-winning science

Ten people blinded by retinitis pigmentosa received a single injection carrying genetic instructions for ChrimsonR, a light-sensitive protein, into their worse-seeing eye — then wore goggles that turned the scene ahead into pulses of amber light their newly sensitive retinas could read. Seven of the ten became more sensitive to light, six reached the threshold for clinically meaningful improvement, and among the eight who completed behavioral testing, four got better at detecting and locating objects, finding doorways, and following lines. The work, led by José-Alain Sahel of the University of Pittsburgh and Botond Roska of the Institute of Molecular and Clinical Ophthalmology Basel with GenSight Biologics, was published in the New England Journal of Medicine — days after optogenetics won its inventors the 2026 Nobel Prize in Physiology or Medicine. No one could read or recognize faces yet, and the researchers call the results exploratory — but for the first time, the single-patient miracle of 2021 has been reproduced across a group.